In the phase II CLEAR-EC trial, cadonilimab combined with lenvatinib produced an objective response rate of 40.6% in platinum-pretreated advanced endometrial cancer, with follow-up extending into longer-term efficacy assessment. The combination targets immune checkpoint signaling alongside angiogenesis inhibition. The trial’s early efficacy supports further development in a disease setting where options are limited after platinum exposure. For the field, the study adds another dataset to support chemo-free and multi-mechanism regimens in later-line gynecologic oncology.
Get the Daily Brief